Etanercept Suppresses Arteritis in a Murine Model of Kawasaki Disease: A Comparative Study Involving Different Biological Agents
International Journal of Vascular Medicine · 2013 · 2013 · 1-10
DOI: 10.1155/2013/543141 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Vascular Medicine, 2013. Verfasst von Ryuji Ohashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Nippon Medical School, 1-1-5 Bunkyo-ku, Sendagi, Tokyo 113-8603, Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Ministry of Education, Culture, Sports, Science, and Technology.
Abstract (Originalsprache)
Coronary arteritis, a complication of Kawasaki disease (KD), can be refractory to immunoglobulin (IVIG) treatment. To determine the most effective alternative therapy, we compared the efficacy of different agents in a mouse model of KD. Vasculitis was induced by injection of Candida albicans water-soluble fractions (CAWS) into a DBA/2 mouse, followed by administration of IVIG, etanercept, methylprednisolone (MP), and cyclosporine-A (CsA). At 2 and 4 weeks, the mice were sacrificed, and plasma cytokines and chemokines were measured. CAWS injection induced active inflammation in the aortic root and coronary arteries. At 2 weeks, the vasculitis was reduced only by etanercept, and this effect persisted for the subsequent 2 weeks. At 4 weeks, IVIG and CsA also attenuated the inflammation, but the effect of etanercept was more significant. MP exerted no apparent effect at 2 or 4 weeks. The suppressive effect exerted by etanercept on cytokines, such as interleukin- (IL-)6, IL-12, IL-13, and tumor necrosis factor- α (TNF- α ), was more evident than that of others. The extent of arteritis correlated with the plasma TNF- α levels, suggesting a pivotal role of TNF- α in KD. In conclusion, etanercept was most effective in suppressing CAWS-induced vasculitis and can be a new therapeutic intervention for KD.
Autor:innen und Institutionen
- Department of Pathology, Nippon Medical School, 1-1-5 Bunkyo-ku, Sendagi, Tokyo 113-8603, Japan.
Förderung
- Ministry of Education, Culture, Sports, Science, and Technology
Zitieren
APA
Ohashi, R., Fukazawa, R., Watanabe, M., Tajima, H., Nagi-Miura, N., Ohno, N., Tsuchiya, S., Fukuda, Y., Ogawa, S., & Itoh, Y. (2013). Etanercept Suppresses Arteritis in a Murine Model of Kawasaki Disease: A Comparative Study Involving Different Biological Agents. International Journal of Vascular Medicine, 2013, 1-10. https://doi.org/10.1155/2013/543141
Vancouver
Ohashi R, Fukazawa R, Watanabe M, Tajima H, Nagi-Miura N, Ohno N, et al. Etanercept Suppresses Arteritis in a Murine Model of Kawasaki Disease: A Comparative Study Involving Different Biological Agents. International Journal of Vascular Medicine. 2013;2013:1-10. doi:10.1155/2013/543141
BibTeX
@article{Ohashi2013,
author = {Ohashi, Ryuji and Fukazawa, Ryuji and Watanabe, Makoto and Tajima, Hanako and Nagi-Miura, Noriko and Ohno, Naohito and Tsuchiya, Shinichi and Fukuda, Yuh and Ogawa, Shunichi and Itoh, Yasuhiko},
title = {Etanercept Suppresses Arteritis in a Murine Model of Kawasaki Disease: A Comparative Study Involving Different Biological Agents},
journal = {International Journal of Vascular Medicine},
year = {2013},
volume = {2013},
pages = {1--10},
doi = {10.1155/2013/543141}
}
EUVIMED